1002 related articles for article (PubMed ID: 12084351)
21. PTEN, but not SHIP2, suppresses insulin signaling through the phosphatidylinositol 3-kinase/Akt pathway in 3T3-L1 adipocytes.
Tang X; Powelka AM; Soriano NA; Czech MP; Guilherme A
J Biol Chem; 2005 Jun; 280(23):22523-9. PubMed ID: 15824124
[TBL] [Abstract][Full Text] [Related]
22. A novel germline mutation of PTEN associated with brain tumours of multiple lineages.
Staal FJ; van der Luijt RB; Baert MR; van Drunen J; van Bakel H; Peters E; de Valk I; van Amstel HK; Taphoorn MJ; Jansen GH; van Veelen CW; Burgering B; Staal GE
Br J Cancer; 2002 May; 86(10):1586-91. PubMed ID: 12085208
[TBL] [Abstract][Full Text] [Related]
23. Hyaluronic acid induces osteopontin via the phosphatidylinositol 3-kinase/Akt pathway to enhance the motility of human glioma cells.
Kim MS; Park MJ; Moon EJ; Kim SJ; Lee CH; Yoo H; Shin SH; Song ES; Lee SH
Cancer Res; 2005 Feb; 65(3):686-91. PubMed ID: 15705860
[TBL] [Abstract][Full Text] [Related]
24. Stem cells. PTEN--coupling tumor suppression to stem cells?
Penninger JM; Woodgett J
Science; 2001 Dec; 294(5549):2116-8. PubMed ID: 11739945
[No Abstract] [Full Text] [Related]
25. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis.
Davies MA; Lu Y; Sano T; Fang X; Tang P; LaPushin R; Koul D; Bookstein R; Stokoe D; Yung WK; Mills GB; Steck PA
Cancer Res; 1998 Dec; 58(23):5285-90. PubMed ID: 9850049
[TBL] [Abstract][Full Text] [Related]
26. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway.
Unoki M; Nakamura Y
Oncogene; 2001 Jul; 20(33):4457-65. PubMed ID: 11494141
[TBL] [Abstract][Full Text] [Related]
27. The biology and clinical relevance of the PTEN tumor suppressor pathway.
Sansal I; Sellers WR
J Clin Oncol; 2004 Jul; 22(14):2954-63. PubMed ID: 15254063
[TBL] [Abstract][Full Text] [Related]
28. Loss of PTEN facilitates HIF-1-mediated gene expression.
Zundel W; Schindler C; Haas-Kogan D; Koong A; Kaper F; Chen E; Gottschalk AR; Ryan HE; Johnson RS; Jefferson AB; Stokoe D; Giaccia AJ
Genes Dev; 2000 Feb; 14(4):391-6. PubMed ID: 10691731
[TBL] [Abstract][Full Text] [Related]
29. Insulin hypersensitivity and resistance to streptozotocin-induced diabetes in mice lacking PTEN in adipose tissue.
Kurlawalla-Martinez C; Stiles B; Wang Y; Devaskar SU; Kahn BB; Wu H
Mol Cell Biol; 2005 Mar; 25(6):2498-510. PubMed ID: 15743841
[TBL] [Abstract][Full Text] [Related]
30. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway.
Zhang J; Choi Y; Mavromatis B; Lichtenstein A; Li W
Oncogene; 2003 Sep; 22(40):6289-95. PubMed ID: 13679867
[TBL] [Abstract][Full Text] [Related]
31. PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein.
Paramio JM; Navarro M; Segrelles C; Gómez-Casero E; Jorcano JL
Oncogene; 1999 Dec; 18(52):7462-8. PubMed ID: 10602505
[TBL] [Abstract][Full Text] [Related]
32. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway.
Sun H; Lesche R; Li DM; Liliental J; Zhang H; Gao J; Gavrilova N; Mueller B; Liu X; Wu H
Proc Natl Acad Sci U S A; 1999 May; 96(11):6199-204. PubMed ID: 10339565
[TBL] [Abstract][Full Text] [Related]
33. In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin.
Tanaka M; Grossman HB
Gene Ther; 2003 Sep; 10(19):1636-42. PubMed ID: 12923562
[TBL] [Abstract][Full Text] [Related]
34. A surprising function for the PTEN tumor suppressor.
Hopkin K
Science; 1998 Nov; 282(5391):1027,1029-30. PubMed ID: 9841444
[No Abstract] [Full Text] [Related]
35. PTEN expression causes feedback upregulation of insulin receptor substrate 2.
Simpson L; Li J; Liaw D; Hennessy I; Oliner J; Christians F; Parsons R
Mol Cell Biol; 2001 Jun; 21(12):3947-58. PubMed ID: 11359902
[TBL] [Abstract][Full Text] [Related]
36. Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells.
St-Germain ME; Gagnon V; Mathieu I; Parent S; Asselin E
Int J Oncol; 2004 May; 24(5):1311-24. PubMed ID: 15067356
[TBL] [Abstract][Full Text] [Related]
37. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells.
Van de Sande T; De Schrijver E; Heyns W; Verhoeven G; Swinnen JV
Cancer Res; 2002 Feb; 62(3):642-6. PubMed ID: 11830512
[TBL] [Abstract][Full Text] [Related]
38. Research on miR-126 in glioma targeted regulation of PTEN/PI3K/Akt and MDM2-p53 pathways.
Chen SR; Cai WP; Dai XJ; Guo AS; Chen HP; Lin GS; Lin RS
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3461-3470. PubMed ID: 31081101
[TBL] [Abstract][Full Text] [Related]
39. PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.
Nakamura JL; Karlsson A; Arvold ND; Gottschalk AR; Pieper RO; Stokoe D; Haas-Kogan DA
J Neurooncol; 2005 Feb; 71(3):215-22. PubMed ID: 15735908
[TBL] [Abstract][Full Text] [Related]
40. Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo.
Ge NL; Rudikoff S
Oncogene; 2000 Aug; 19(36):4091-5. PubMed ID: 10962569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]